Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2022 | Strategies to prevent resistance in CLL

Sigrid Skånland • 21 Mar 2022
ESH CLL 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

Sigrid Skånland, PhD, Oslo University Hospital, Oslo, Norway, briefly summarizes methods to prevent resistance to targeted therapies in chronic lymphocytic leukemia (CLL). Dr Skånland draws focus on one strategy, which is to target several pathways by combining different agents, such as venetoclax and ibrutinib. Dr Skånland concludes by mentioning the possibility of using fixed duration therapy in treatment, and the benefits of this method of treatment in cases of relapsed disease. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

More from Sigrid Skånland

3:22
Treatment approaches to idelalisib-refractory CLL
Sigrid Skånland • 21 Mar 2022
1:20
Mechanisms of resistance to targeted therapies in CLL
Sigrid Skånland • 21 Mar 2022
1:18
Drug sensitivity testing in CLL
Sigrid Skånland • 21 Mar 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals